Novartis’ Tekturna May Prevent Toxic Consequences of Obesity

The disappointing news for manufacturers of anti-obesity treatments could mean doctors will increasingly look for drugs for obese patients that protect them against the adverse consequences of visceral fat such as the new class of direct renin inhibitors (DRI).
Pharma Times